Incyte (NASDAQ:INCY) Releases Earnings Results, Beats Estimates By $0.33 EPS

Posted by on Oct 31st, 2026

Incyte (NASDAQ:INCY – Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, beating the consensus estimate of ($3.93) by $0.33, FiscalAI reports. The firm had revenue of $1.56 billion during the quarter, compared to the consensus estimate of $1.46 billion. Incyte had a net margin of 6.71% and a return on equity of 7.92%. The company’s revenue was up 14.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.26 earnings per share.

Here are the key takeaways from Incyte’s conference call:

  • Strong quarterly performance and raised guidance: Third-quarter revenue and net sales both increased 14% year over year to $1.56 billion and $1.32 billion, respectively. Incyte raised full-year 2026 net sales guidance to $5.21 billion–$5.30 billion, driven by OPZELURA and hematology/oncology products.
  • OPZELURA continued to drive growth: OPZELURA sales rose 36% to $255 million, with underlying U.S. demand up 24% on a pro forma basis and strong new-patient growth. European approval for moderate atopic dermatitis and potential additional HS applications could further expand the franchise.
  • Late-stage pipeline advanced across multiple therapeutic areas: Incyte highlighted encouraging early data for its G12D inhibitor in pancreatic and colorectal cancer and its TGFβR2×PD-1 bispecific in colorectal cancer. The company now has six Phase III programs and expects additional data and regulatory milestones over the next 12–18 months.
  • CALR-directed MPN program remains a major value driver: Management expects to present more mature frontline data for INCA033989 at ASH and plans to advance a potentially more potent, longer-acting next-generation CALR antibody into the clinic in early 2027. The company is also discussing alternative composite endpoints with the FDA that could better capture disease modification.
  • Pipeline investment and portfolio pruning create near-term risks: GAAP operating expenses surged 146%, largely due to the $1.23 billion Vega acquisition-related R&D charge, while the company discontinued enrollment in the Phase III platinum-resistant ovarian cancer study for its CDK2 inhibitor. Jakafi sales grew only 4% because of pricing effects, and management continues to prepare for retaining only 10%–30% of the franchise by 2029.

Incyte Price Performance

NASDAQ INCY traded up $3.59 during midday trading on Friday, hitting $120.39. 2,840,375 shares of the company traded hands, compared to its average volume of 1,868,128. The company has a market cap of $24.40 billion, a PE ratio of 64.04, a price-to-earnings-growth ratio of 4.83 and a beta of 0.74. The company’s 50-day simple moving average is $120.49 and its 200-day simple moving average is $108.14. Incyte has a 52 week low of $89.25 and a 52 week high of $132.60.

Analyst Ratings Changes

Several research analysts have commented on INCY shares. Stifel Nicolaus raised their price objective on Incyte from $145.00 to $157.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Truist Financial upped their target price on Incyte from $105.00 to $115.00 and gave the stock a “hold” rating in a report on Wednesday, October 14th. Royal Bank Of Canada increased their price target on Incyte from $114.00 to $117.00 and gave the stock a “sector perform” rating in a research report on Friday. Barclays raised their price target on Incyte from $139.00 to $143.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Piper Sandler lifted their price objective on Incyte from $110.00 to $130.00 and gave the company an “overweight” rating in a report on Monday, August 17th. Twelve research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $132.90.

Read Our Latest Stock Analysis on Incyte

Insider Activity

In other news, insider Pablo Cagnoni sold 10,801 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total value of $1,356,173.56. Following the completion of the transaction, the insider directly owned 183,200 shares of the company’s stock, valued at approximately $23,002,592. The trade was a 5.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 16.20% of the company’s stock.

More Incyte News

Here are the key news stories impacting Incyte this week:

  • Positive Sentiment: Incyte reported third-quarter revenue of $1.56 billion, up 14% year over year and above the $1.46 billion analyst estimate. Adjusted loss of $3.60 per share was narrower than expected, helping support the stock. INCY Q3 Loss Narrower Than Expected, Sales Beat, FY’26 View Raised
  • Positive Sentiment: The company raised 2026 total net-sales guidance to $5.21 billion-$5.30 billion, from $5.13 billion-$5.26 billion previously. Opzelura guidance was also increased to $1.10 billion-$1.12 billion, reflecting continued demand. Incyte signals 2026 net sales outlook as Opzelura guidance rises
  • Positive Sentiment: Product trends were favorable: Opzelura sales rose 36% to $255 million, while hematology and oncology portfolio sales increased 38% to $235 million. Jakafi and Jakafi XR sales grew 4% to $827 million. Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales Guidance
  • Positive Sentiment: Barclays raised its price target from $139 to $143 and maintained an “overweight” rating, implying substantial upside and reinforcing the bullish reaction. Barclays Incyte analyst recommendation
  • Neutral Sentiment: Wells Fargo lowered its target slightly to $127 and kept an “equal weight” rating, while RBC raised its target to $117 but retained a “sector perform” rating. The changes indicate limited conviction among some analysts. Wells Fargo Incyte analyst recommendation
  • Negative Sentiment: Incyte posted a GAAP loss largely because of a $1.23 billion in-process research and development charge tied to the Vega Therapeutics acquisition. The unusual charge obscures underlying operating strength and may keep investors focused on acquisition execution. Incyte Posts Q3 Loss on Vega Acquisition Charge

Incyte Company Profile

(Get Free Report)

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.

Read More

Earnings History for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.